Abstract: Objective To analyze the efficacy and safety of rifampicin in the treatment of 11 patients with persistent hepatocellular secretory failure (PHSF). Methods Patients who were hospitalized in Nanjing Second Hospital from March 2022 to March 2024 and clinically diagnosed with PHSF and received rifampicin treatment were selected. General information, clinical data and laboratory data were collected, and the laboratory data before and after rifampicin treatment were compared. Results The average age of the 11 PHSF patients was 55.4 years old. The average level of total bilirubin before taking rifampicin was 463.15 μmol/L. All patients received rifampicin treatment at a dose of 150~300 mg/d for a course of 3~4 weeks. The changes in relevant indicators before and after treatment were compared. After treatment, TBil decreased to 51.5 (40.1, 192.8) μmol/L, DBil decreased to 44.5 (30.5, 139.6) μmol/L, and TBA decreased to 18.1 (13.6, 78.5) μmol/L, with statistically significant differences compared with those before treatment (P<0.05). After treatment, mild elevation of ALT and AST was observed in one patient, and absolute values of white blood cells and neutrophils decreased to varying degrees was observed in 3 patients. No abnormal renal function was found in all patients after rifampicin treatment. Conclusion Rifampicin shows good efficacy and high safety in the treatment of patients with persistent hepatocellular secretory failure, but randomized controlled clinical studies are still needed for further confirmation.

Key words: Rifampicin, Persistent hepatocellular secretory failure, Hyperbilirubinemia